Bausch Health Companies (DB:BVF) - Aandelenkoers, Nieuws & Analyse

BVF Overzicht aandelen

Bausch Health Companies Inc. is een gediversifieerd bedrijf in farmaceutische specialiteiten en medische apparatuur in de Verenigde Staten en internationaal. Meer informatie

BVF fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Verhandeld tegen 84.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 218.28% per jaar groeien

De winst is de afgelopen 5 jaar met 34.6% per jaar gegroeid

Risicoanalyse

Negatief eigen vermogen

Bausch Health Companies Inc. Concurrenten

Dermapharm Holding

XTRA:DMP

€2.0b

Bayer

XTRA:BAYN

€18.8b

PharmaSGP Holding

XTRA:PSG

€304.6m

Merck KGaA

XTRA:MRK

€61.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bausch Health Companies
Historische aandelenkoersen
Huidige aandelenkoers	US$8.66
52 Week Hoogtepunt	US$9.82
52 Week Laag	US$4.69
Bèta	0.74
11 maand verandering	17.12%
3 maanden verandering	68.01%
1 Jaar Verandering	n/a
33 jaar verandering	-58.46%
5 jaar verandering	-66.49%
Verandering sinds IPO	-4.21%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BVF	DE Pharmaceuticals	DE Markt
7D	0%	1.6%	1.1%
1Y	n/a	-19.0%	7.2%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe BVF presteerde ten opzichte van de German Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe BVF presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is BVF's price volatile compared to industry and market?
BVF volatility
BVF Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: Er zijn geen gegevens beschikbaar.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BVF in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. is een gediversifieerd bedrijf in farmaceutische specialiteiten en medische hulpmiddelen in de Verenigde Staten en internationaal. Het bedrijf ontwikkelt, produceert en verkoopt een scala aan producten, voornamelijk op het gebied van gastro-enterologie, hepatologie, neurologie, dermatologie, internationale farmaceutica, receptvrije producten (OTC), esthetische medische hulpmiddelen en ooggezondheid. Het bedrijf is actief in vijf segmenten: Salix, International, Solta Medical, Diversified en Bausch + Lomb.

Bausch Health Companies Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Bausch Health Companies zich tot de beurswaarde?
BVF fundamentele statistieken
Marktkapitalisatie	€2.83b
Inkomsten(TTM)	-€168.48m
Inkomsten(TTM)	€8.97b

0.3x

P/S-verhouding

-16.8x

Koers/Winstverhouding

Is BVF overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BVF resultatenrekening (TTM)
Inkomsten	US$9.47b
Kosten van inkomsten	US$2.76b
Brutowinst	US$6.71b
Overige uitgaven	US$6.89b
Inkomsten	-US$178.00m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.48
Brutomarge	70.87%
Nettowinstmarge	-1.88%
Schuld/Eigen Vermogen Verhouding	-8,887.2%

Hoe presteerde BVF op de lange termijn?

Bekijk historische prestaties en vergelijking

BVF Overzicht aandelen

Beloningen

Risicoanalyse

Bausch Health Companies Inc. Concurrenten

XTRA:DMP

€2.0b

XTRA:BAYN

€18.8b

XTRA:PSG

€304.6m

XTRA:MRK

€61.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Second quarter 2024 earnings released: EPS: US$0.027 (vs US$0.071 in 2Q 2023)

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.55 loss in 1Q 2023)

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

No longer forecast to breakeven

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold €708k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Investor sentiment improved over the past week

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit